Carl Zeiss Meditec AG (XSWX:AFX) Stock Based Compensation: CHF0 Mil (TTM As of Dec. 2025)


XSWX:AFX Carl Zeiss Meditec AG XSWX:AFX
80 GF Score
Price CHF25.10
GF Value CHF68.94
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Carl Zeiss Meditec AG Stock Based Compensation?

Carl Zeiss Meditec AG XSWX:AFX 80 Stock Based Compensation is CHF0 Mil as of Dec. 2025. GuruFocus rates XSWX:AFX with a GF Score™ of 80/100 and a GF Value™ of CHF68.94 (Significantly Undervalued). The stock has 4 warning signs investors should review.

Carl Zeiss Meditec AG's Stock Based Compensation for the three months ended in Dec. 2025 was CHF0 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 was CHF0 Mil.

Carl Zeiss Meditec AG Stock Based Compensation Related Terms

Carl Zeiss Meditec AG Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Carl Zeiss Meditec AG's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Carl Zeiss Meditec AG Stock Based Compensation Chart

Carl Zeiss Meditec AG Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Carl Zeiss Meditec AG Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XSWX:AFX
80GF Score
Carl Zeiss Meditec AG XSWX:AFX
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Carl Zeiss Meditec AG Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF0 Mil.

What does a Stock Based Compensation of CHF0 Mil mean?
Carl Zeiss Meditec AG (XSWX:AFX) has a Stock Based Compensation of CHF0 Mil as of Dec. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Carl Zeiss Meditec AG and its competitors.
Is Carl Zeiss Meditec AG's Stock Based Compensation too high?
Carl Zeiss Meditec AG's current Stock Based Compensation is CHF0 Mil. Overall, Carl Zeiss Meditec AG has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Carl Zeiss Meditec AG's Stock Based Compensation compare to ISRG and BDX?
Carl Zeiss Meditec AG's Stock Based Compensation of CHF0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Medical Devices & Instruments company?
A good Stock Based Compensation depends on the Medical Devices & Instruments industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Carl Zeiss Meditec AG and its competitors. Carl Zeiss Meditec AG's current Stock Based Compensation is CHF0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carl Zeiss Meditec AG stock overvalued right now?
Based on GuruFocus' analysis, Carl Zeiss Meditec AG (XSWX:AFX) is currently considered Significantly Undervalued. The stock's GF Value™ is CHF68.94, compared to a current price of CHF25.10 — trading 63.6% below its estimated fair value. The current Stock Based Compensation is CHF0 Mil. Carl Zeiss Meditec AG's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Carl Zeiss Meditec AG (XSWX:AFX), the current Stock Based Compensation is CHF0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Carl Zeiss Meditec AG (XSWX:AFX) Overvalued in 2026?

Based on GuruFocus' analysis, Carl Zeiss Meditec AG stock appears to be undervalued. The current stock price of CHF25.10 is trading 63.6% below its estimated GF Value™ of CHF68.94. GuruFocus considers Carl Zeiss Meditec AG to be Significantly Undervalued.

Key valuation signals for XSWX:AFX:

  • Stock Based Compensation: CHF0 Mil
  • GF Value™: CHF68.94 vs. price of CHF25.10 (63.6% below fair value)
  • GF Score™: 80/100 with 4 warning signs

No single metric tells the full story. See the XSWX:AFX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Carl Zeiss Meditec AG Business Description

Address Goschwitzer Strasse 51-52, Jena, TH, DEU, 07745
Carl Zeiss Meditec is one of the largest visioncare technology companies in the world, and it operates in two segments: ophthalmic devices and microsurgery. OPT, which made up about 75% of sales in 2025, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.
80GF Score

Get the complete analysis for XSWX:AFX

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF25.10
Price
CHF68.94
GF Value